Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study
We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week. Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema. On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by ...